Printer Friendly

A. L. LABORATORIES, INC. ANNOUNCES ACQUISITION

 FORT LEE, N.J., March 10 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today announced that Barre-National, Inc., the company's liquid pharmaceutical subsidiary, has acquired the business and operating assets of NASKA Pharmacal Co. from Rugby-Darby Group Companies, Inc. Terms of the transaction were not disclosed.
 The major asset acquired is NASKA's modern 82,000 square foot manufacturing facility located in Lincolnton, North Carolina. Completed in 1990, this facility was specifically designed for the production of specialty dosage form pharmaceuticals, primarily oral liquids and topical ointments and creams. A supply agreement has been reached which provides for continued sale, under the Company's customary commercial terms, of products currently produced at NASKA for Rugby-Darby and selected other specialized products from A. L. Laboratories' U.S. Pharmaceutical operations, including liquids from Barre-National, ointments and creams from NMC Laboratories and suppositories from Able Laboratories.
 Commenting on the announcement, Jeffrey E. Smith, executive vice president and member of the office of the chief executive of A. L. Laboratories, Inc. said, "We have made an exciting and important addition to our existing U.S. Pharmaceutical operations which today focuses on specialized products and markets with particular emphasis on oral liquids and topical ointments and creams. The NASKA business and this modern, specialized production facility, fully staffed with an experienced management group and work force, complements our existing business and supports our aggressive growth plans."
 George S. Barrett, president of Barre-National, Inc. said, "This acquisition provides significant strategic benefits to our U.S. Pharmaceuticals business. As we continue to position our organization for growth, the addition of this business strengthens our product mix and creates opportunities to more efficiently utilize our manufacturing capabilities to better serve our customers."
 A. L. Laboratories is a multinational manufacturer and marketer of specialized value-added branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, Washington, Denmark, Indonesia and with this acquisition, North Carolina.
 -0- 3/10/93
 /CONTACT: Iris Daniels of A. L. Laboratories, Inc., 201-947-7774, or June Filingeri of Morgen-Walke Associates, 212-986-5900, for A. L. Laboratories, Inc./
 (BMD)


CO: A.L. Laboratories, Inc. ST: New Jersey IN: MTC SU: TNM

SH -- NY014 -- 4834 03/10/93 09:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 10, 1993
Words:366
Previous Article:TOYS 'R' US REPORTS RECORD SALES AND EARNINGS NET EARNINGS INCREASED 29 PERCENT
Next Article:1992 GOODY EARNINGS INCREASED 166 PERCENT EXCLUDING SPECIAL CHARGES
Topics:


Related Articles
A. L. LABORATORIES ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT ITS BARRE-NATIONAL SUBSIDIARY
A. L. LABORATORIES REPORTS 1992 FULL-YEAR AND FOURTH QUARTER EARNINGS
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF EPINEPHRINE MIST
A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
A. L. LABORATORIES NAMES BETH POSNACK HECHT AS CORPORATE COUNSEL
A. L. LABORATORIES NAMES JIM FLYNN VICE PRESIDENT, CORPORATE DEVELOPMENT
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF CLOTRIMAZOLE VAGINAL CREAM
A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA
A. L. LABORATORIES DECLARES REGULAR QUARTERLY CASH DIVIDEND
BRISTOL-MYERS SQUIBB TO ACQUIRE CALGON VESTAL LABORATORIES FROM MERCK

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters